* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
Noile-Immune Biotech (TSE:4893) Earnings Power Value (EPV) Explanation
Assumption: Current profitability is sustainable.
Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.
Be Aware
Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.
Noile-Immune Biotech Earnings Power Value (EPV) Related Terms
Noile-Immune Biotech Earnings Power Value (EPV) Historical Data
* Premium members only.
The historical data trend for Noile-Immune Biotech's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noile-Immune Biotech Earnings Power Value (EPV) Chart
TSE:4893 vs VRTX, REGN, ALNY: Earnings Power Value (EPV) Comparison
For the Biotechnology subindustry, Noile-Immune Biotech's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noile-Immune Biotech Earnings Power Value (EPV) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Noile-Immune Biotech's Earnings Power Value (EPV) falls into.
Noile-Immune Biotech Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
What does a Earnings Power Value (EPV) of 円86.45 mean?
Noile-Immune Biotech (TSE:4893) has a Earnings Power Value (EPV) of 円86.45 as of Mar26. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Noile-Immune Biotech and its competitors.
Is Noile-Immune Biotech's Earnings Power Value (EPV) too high?
Noile-Immune Biotech's current Earnings Power Value (EPV) is 円86.45. Overall, Noile-Immune Biotech has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Earnings Power Value (EPV) compare to VRTX and REGN?
Noile-Immune Biotech's Earnings Power Value (EPV) of 円86.45 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Biotechnology company?
A good Earnings Power Value (EPV) depends on the Biotechnology industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Noile-Immune Biotech and its competitors. Noile-Immune Biotech's current Earnings Power Value (EPV) is 円86.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.36, compared to a current price of 円121.00 — trading 2675.2% above its estimated fair value. The current Earnings Power Value (EPV) is 円86.45. Noile-Immune Biotech's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Earnings Power Value (EPV) is 円86.45 as of Mar26. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?
Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued.
The current stock price of 円121.00 is trading 2675.2% above its estimated GF Value™ of 円4.36.
GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.
Key valuation signals for TSE:4893:
Earnings Power Value (EPV): 円86.45
GF Value™: 円4.36 vs. price of 円121.00 (2675.2% above fair value)
No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
53GF Score
Get the complete analysis for TSE:4893
Earnings Power Value (EPV) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4893 has been successfully added to your 
